Adamj Olszewski News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adamj olszewski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adamj Olszewski Today - Breaking & Trending Today

Olszewski Recaps Results of Mosunetuzumab in Elderly/Unfit DLBCL

Adam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. ....

Brown University , Rhode Island , United States , Rhode Island Hospital , Adamj Olszewski , Adamj Olszewski , Elderly Unfit Patients With Previously Untreated Diffuse Largeb Cell Lymphoma , Diffuse Largeb Cell Lymphoma , Phase 1b 2 Study Nct03677154 ,

Mosunetuzumab Maintains Efficacy/Survival Benefit in Elderly Patients With DLBCL

In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma. ....

Rhode Island , United States , Brown University , Rhode Island Hospital , Adamj Olszewski , Diffuse Largeb Cell Lymphoma , Phase 1b 2 Study ,

Mosunetuzumab with polatuzumab vedotin effective in range of age groups with DLBCL

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.The overall response rate was 54% in younger patients and 72% in older patients, Adam J. Olszewski, MD, presenting author, said. ....

Rhode Island , United States , Mindy Valcarcel , Bycory Perla , Adamj Olszewski , Brown Physicians Inc , Brown University Warren Alpert Medical School , Adaptive Biotechnologies Genentech , Blue Cross , Blue Shield , Brown Physicians , Brown University , Warren Alpert Medical School ,

Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment

Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment
Research by Rutgers Cancer Institute of New Jersey and RWJBarnabas Health researcher and international collaborators can help identify prognosis and stratify risk
News provided by
Share this article
(PRNewsfoto/Rutgers Cancer Institute of New Jersey and RWJBarnabas Health)
NEW BRUNSWICK, N.J., Jan. 28, 2021 /PRNewswire/ Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. The research from the Burkitt Lymphoma International Prognostic Index Consortium is published in the January 2021 online i ....

Cancer Institute Of New Jersey , New Jersey , United States , New Brunswick , Krista Didzbalis , Adamj Olszewski , Andrewm Evens , Lymphoma Program At Rutgers Cancer Institute , Rutgers Cancer Institute Of New Jersey , Cancer Center , World Health Organization , National Cancer Comprehensive Center , Rwjbarnabas Health , Burkitt Lymphoma International Prognostic Index , Clinical Services , Oncology Service Line , National Cancer , Rutgers Cancer Institute , Burkitt Lymphoma International Prognostic Index Consortium , Lifespan Cancer Institute , Comprehensive Cancer Center , Associate Director , Lymphoma Program , Medical Director , Warren Alpert Medical School , Brown University ,